Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand
ObjectiveThis study aimed to assess the financial impact of different adoption rates of insulin glargine (IGlar) treatment compared to isophane protamine (neutral protamine hagedorn [NPH]) insulin treatment for patients with type-2 diabetes (T2D) and severe hypoglycemia in Thailand from the payer’s...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2024.1415908/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841540105231138816 |
|---|---|
| author | Unchalee Permsuwan Unchalee Permsuwan Chaicharn Deerochanawong |
| author_facet | Unchalee Permsuwan Unchalee Permsuwan Chaicharn Deerochanawong |
| author_sort | Unchalee Permsuwan |
| collection | DOAJ |
| description | ObjectiveThis study aimed to assess the financial impact of different adoption rates of insulin glargine (IGlar) treatment compared to isophane protamine (neutral protamine hagedorn [NPH]) insulin treatment for patients with type-2 diabetes (T2D) and severe hypoglycemia in Thailand from the payer’s perspective.MethodsThe budget impact analysis (BIA) model over a period of 5 years was used to estimate the net budget impact (NBI) of IGlar treatment by comparing the total budget expenditures under two scenarios: scenario 1 involved only NPH insulin and scenario 2 included the introduction of IGlar. The total budget included either the cost of insulin or a combination of the costs of insulin and the expense related to severe hypoglycemia. Scenario 2 started at 20% uptake of IGlar and a yearly increase of 20%. NBI was calculated as the difference between the total budgets of scenarios 1 and 2. NBI and one-way sensitivity analyses were conducted for evaluation.ResultsConsidering only the cost of insulin, the use of IGlar for patients with T2D and severe hypoglycemia resulted in a yearly average NBI of 174.9 million Thai baht (THB) (5.1 million USD). However, when the cost related to severe hypoglycemia was included, the total budget incurred from scenario 2 was less than that of scenario 1, leading to a negative NBI or cost savings.ConclusionThe NBI of IGlar adoption would be substantial when considering only the cost of insulin; however, the significant benefit of IGlar in terms of a lower rate of severe hypoglycemia compared with NPH insulin would clearly offset the additional cost of IGlar. |
| format | Article |
| id | doaj-art-42ea41be0d404ca2b4abd6c79e1ddff1 |
| institution | Kabale University |
| issn | 2296-2565 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj-art-42ea41be0d404ca2b4abd6c79e1ddff12025-01-14T06:10:37ZengFrontiers Media S.A.Frontiers in Public Health2296-25652025-01-011210.3389/fpubh.2024.14159081415908Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in ThailandUnchalee Permsuwan0Unchalee Permsuwan1Chaicharn Deerochanawong2Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, ThailandCenter for Medical and Health Technology Assessment (CM-HTA), Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, ThailandRajavithi Hospital, College of Medicine, Ministry of Public Health, Rangsit University, Bangkok, ThailandObjectiveThis study aimed to assess the financial impact of different adoption rates of insulin glargine (IGlar) treatment compared to isophane protamine (neutral protamine hagedorn [NPH]) insulin treatment for patients with type-2 diabetes (T2D) and severe hypoglycemia in Thailand from the payer’s perspective.MethodsThe budget impact analysis (BIA) model over a period of 5 years was used to estimate the net budget impact (NBI) of IGlar treatment by comparing the total budget expenditures under two scenarios: scenario 1 involved only NPH insulin and scenario 2 included the introduction of IGlar. The total budget included either the cost of insulin or a combination of the costs of insulin and the expense related to severe hypoglycemia. Scenario 2 started at 20% uptake of IGlar and a yearly increase of 20%. NBI was calculated as the difference between the total budgets of scenarios 1 and 2. NBI and one-way sensitivity analyses were conducted for evaluation.ResultsConsidering only the cost of insulin, the use of IGlar for patients with T2D and severe hypoglycemia resulted in a yearly average NBI of 174.9 million Thai baht (THB) (5.1 million USD). However, when the cost related to severe hypoglycemia was included, the total budget incurred from scenario 2 was less than that of scenario 1, leading to a negative NBI or cost savings.ConclusionThe NBI of IGlar adoption would be substantial when considering only the cost of insulin; however, the significant benefit of IGlar in terms of a lower rate of severe hypoglycemia compared with NPH insulin would clearly offset the additional cost of IGlar.https://www.frontiersin.org/articles/10.3389/fpubh.2024.1415908/fullbudget impact analysisinsulin glargineNPH insulindiabetesThailand |
| spellingShingle | Unchalee Permsuwan Unchalee Permsuwan Chaicharn Deerochanawong Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand Frontiers in Public Health budget impact analysis insulin glargine NPH insulin diabetes Thailand |
| title | Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand |
| title_full | Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand |
| title_fullStr | Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand |
| title_full_unstemmed | Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand |
| title_short | Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand |
| title_sort | budget impact analysis of insulin glargine vs isophane protamine insulin treatment for patients with type 2 diabetes and severe hypoglycemia in thailand |
| topic | budget impact analysis insulin glargine NPH insulin diabetes Thailand |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2024.1415908/full |
| work_keys_str_mv | AT unchaleepermsuwan budgetimpactanalysisofinsulinglarginevsisophaneprotamineinsulintreatmentforpatientswithtype2diabetesandseverehypoglycemiainthailand AT unchaleepermsuwan budgetimpactanalysisofinsulinglarginevsisophaneprotamineinsulintreatmentforpatientswithtype2diabetesandseverehypoglycemiainthailand AT chaicharndeerochanawong budgetimpactanalysisofinsulinglarginevsisophaneprotamineinsulintreatmentforpatientswithtype2diabetesandseverehypoglycemiainthailand |